1 month | 3 month | 1 year | 3 year | 5 year | Since Inception | Inception Date |
---|---|---|---|---|---|---|
0.54% | -0.73% | 2.88% | 7.72% | 8.02% | 10.27% | 18 Feb 2014 |
Management Fee | Performance Fee | Morningstar Total Cost Ratio |
---|---|---|
1.25% | - | 1.25% |
Claremont Global has a concentrated portfolio of no more than 15 businesses. The Claremont Global strategy was established in 2011 and has since demonstrated a consistent track record of outperformance since inception.
We own companies with durable competitive advantages, resilient earnings, financial strength and seasoned management teams. We are disciplined about valuation and our purchases are made at a discount to our assessment of fair value, providing investors both a margin of safety and upside potential. We do not buy companies based on macroeconomic or political views - be it interest rates, commodity prices, industrial production or regulatory or political changes. We do not own complex, highly regulated, or cyclical businesses, nor do we own turnarounds.
This highly focused research effort allows us the time to focus on the three things that really matter to us:
1. What is the company's competitive advantage and how long can it endure?
2. Is the company run by honest and capable management who allocate capital rationally?
3. Is the company trading at a fair price relative to our assessment of intrinsic value?
As a result, we take the time to get to know our companies and over the years build up a deep collective knowledge of their industry, the company, the management, and their competitors. We then wait patiently until the market provides a fair entry point.
Access our Investor Manual and learn about our philosophy and process here.
Our investment philosophy is conservative and straightforward, and based on four clear and demanding criteria:
Business quality – We look to own businesses whose intrinsic value is rising over time. This is achieved by earnings growth and returns on invested capital well above their cost of capital on a sustainable basis and where the risk of erosion of these returns is regarded as low.
Balance sheet quality – We want businesses with low levels of financial risk. Typically this means net debt to EBITDA of below 2.5x, high-interest cover ratios, and moderate levels of pension and other off-balance sheet liabilities.
Management quality – We look for management that allocates capital to the benefit of shareholders. This means an emphasis on small, accretive acquisitions over large deals where value destruction is common. We also favour management that repurchases shares when they are attractively priced and pays consistent dividends.
Attractive valuation – We aim to own businesses that satisfy the above three criteria only when they trade at a meaningful discount to intrinsic value. This margin of safety is integral to our capital preservation approach and also key to achieving our absolute return objective.
The Fund will invest in equity securities listed on financial markets located outside of Australia. The listed securities may be chosen from stocks included in the Benchmark but may also include stocks not included in the Benchmark. The cash holding will rise and fall given the attractiveness of individual stocks based on the Investment Manager’s selection criteria. Cash will generally be held in at-call Australian bank deposits denominated in foreign currencies and converted back to Australian dollars when required.
The Fund investments are subject to the following constraints/restrictions:
The Fund will only invest in Derivatives for currency hedging purposes. Currency hedging is subject to a minimum of 90% of the gross asset value of the Fund. The hedge may not provide complete protection from adverse currency movements.
Short selling of equity securities or equity indexes is not permitted.
Top Five Holdings (31 August 2025)
Top five* |
Region |
Sector |
Agilent Technologies |
US |
Healthcare |
Amazon |
US |
Information Technology |
Marsh McLennan |
US |
Business Services |
Microsoft |
US |
Information Technology |
Zoetis |
US |
Healthcare |
* Please note the top 5 holding are in alphabetical order.
Stay up to date with our monthly and quarterly Fund Reports, which provide detailed insights into portfolio performance, portfolio weightings, top holdings, and commentary on key market movers. Explore the latest reports here.
Claremont Funds Management Pty Ltd is the Investment Manager (ACN 649 280 142, ABN 38 649 280 142, CAR No. 001289207) for the Claremont Global Fund (ARSN 166 708 792) and Claremont Global Fund (Hedged) (ARSN 166 708 407), which are together referred to as the ‘Funds’. Equity Trustees Limited (ACN 004 031 298, AFSL 240957) (“Equity Trustees”) is the Responsible Entity of the Funds. For further information on the Funds please refer to each Fund’s PDS and Target Market Determination which is available at www.claremontglobal.com.au. A Target Market Determination is a document which is required to be made available from 5 October 2021. It describes who this financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where the Target Market Determination for this financial product may need to be reviewed.
The information may contain general advice. Any general advice provided has been prepared without taking into account your objectives, financial situation or needs. Before acting on the advice, you should consider the appropriateness of the advice with regard to your objectives, financial situation and needs. Past performance is not a reliable indicator of future performance. The Investment Manager and the Responsible Entity (Parties) give no warranty, representation or guarantee as to the accuracy, completeness or reliability of the information contained in this report. The Parties do not accept, except to the extent permitted by law, responsibility for any loss, claim, damages, costs or expenses arising out of, or in connection with, the information contained.
Claremont is a boutique fund manager located in Sydney, Australia. We run a high-conviction, fundamental strategy and only invest in international equities. Our evidence-based and rigorous bottom-up approach allows us to identify the world’s best companies. If these businesses satisfy our specific criteria and strict valuation methodology the team will consider investing in them for the long term.
Our investment philosophy can be described as buying quality businesses at a reasonable price. We look to acquire these securities at a discount to our estimate of their intrinsic value. We explicitly exclude more cyclical or leveraged industries including banks and resources. We invest in companies whose earnings growth drives intrinsic value, whilst their inherent quality (high margins, strong balance sheets and cash flow) will help to protect client capital in difficult markets.
Bob is a seasoned investor in global markets and has been refining his quality growth process for more than 30 years.
Zimbabwean born, Bob has lived and worked in Africa, the UK and Australia. He started his career with Anglo American and Fleming Martin in Africa, before joining Seilern Investment Management in London in 2002 as a Portfolio Manager and Head of Research.
He joined the strategy in 2012 as Senior Research Analyst and in 2017 was appointed Head of Claremont Global and co-Portfolio Manager.
Bob leads Claremont with an egalitarian approach, empowering the team to individually play to their strengths within a highly collaborative environment.
He holds a BA in Politics and Economics from the University of West Australia and is a CFA Charterholder.
Adam has more than 25 years’ experience in financial markets, having previously worked as an analyst and Portfolio Manager with UBS’s Fundamental Investment Group and at a London-based, absolute return fund. In the earlier stages of his career, Adam worked in investment banking at Credit Suisse First Boston, and at UBS in Sydney and London, advising on mergers and acquisitions, and capital raisings.
Adam joined Claremont Global in 2017, as co-Portfolio Manager with Bob Desmond.
He has a Bachelor of Commerce, majoring in Finance (Honours) from The University of Melbourne.
Chris is Mexican born and has more than 15 years’ experience in equity research. He joined Evans & Partners in 2011 as Investment Analyst where he covered Australian equities.
Chris joined Claremont Global in 2018.
He holds a Bachelor of Finance from La Trobe University and a Master of Applied Finance from Monash University.
Luke joined the Claremont Global team in 2017 and has more than 8 years’ experience investing in global markets.
He has completed a Bachelor of Engineering (Honours) majoring in Civil Engineering and a Bachelor of Commerce majoring in Finance from Monash University. He is a CFA Charterholder.
Monthly Report - August 2025
The issuer of this product is identified at the top of this page. The PDS and target market determination for the product are available in the Documents section of this listing. Prospective investors should consider the PDS before deciding to acquire the product. This product listing was vetted by and approved by the product issuer identified above before publishing. Investment Markets (Aust) Pty Ltd AFSL 527875 (IM) is not the issuer of the product.
IMPORTANT STATEMENT ABOUT YOUR USE OF THIS SITE
Information on this site is intended for Australian users only.
This site is operated by Investment Markets (Aust) Pty Ltd. (ACN 634 057 248) (IMA, we, us and our), the holder of Australian Financial Services Licence (AFSL) no. 527875. The content is provided solely for information purposes, is not a recommendation or an offer to buy or sell a security, and is not warranted to be correct, complete or accurate. To the extent permitted by law, neither IMA, its affiliates, nor the content providers (such as the issuers of securities who appear on the site) are responsible for any investment decisions, damages or losses resulting from, or related to, the content, data and analyses or their use. The investment products on this site and any statements made about them by their issuers are not vetted, verified or researched by IMA. The presence of an investment product on this site should not be interpreted as an implied endorsement of it by IMA. Certain content provided may constitute a summary or extract of another document such as a Product Disclosure Statement. To the extent any content is general advice, it has been prepared by IMA. Any general advice has been provided without reference to your investment objectives, financial situations or needs. For more information refer to our Financial Services Guide. To obtain advice tailored to your situation, contact a financial advisor. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (or other offer document) before making any decision to invest. Past performance does not necessarily indicate an investment product’s future performance. The content is current as at date of initial publication and may not be current as at your date of viewing. For a more complete understanding of all the terms and conditions of your use of this site click here.
1 For use in Australia: © 2025 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its affiliates or content providers; (2) may not be copied, adapted or distributed; (3) is not warranted to be accurate, complete or timely and 4) has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), subsidiary of Morningstar. Neither Morningstar nor its content providers are responsible for any damages arising from the use and distribution of this information. Past performance is no guarantee of future results.
Any general advice has been provided without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide at http://www.morningstar.com.au/s/fsg.pdf. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Morningstar's publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Morningstar's full research reports are the source of any Morningstar Ratings and are available from Morningstar or your advisor. Past performance does not necessarily indicate a financial product's future performance. To obtain advice tailored to your situation, contact a financial advisor. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782.